Tags

Type your tag names separated by a space and hit enter

Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum.
Clin Cancer Res. 2004 Jul 15; 10(14):4761-8.CC

Abstract

PURPOSE

The purpose is to study the prognostic significance of tissue expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor (TATI) and serum concentration of trypsinogen-2, trypsin-2-API (complex of trypsin-2 with alpha-1-proteinase inhibitor), and TATI in epithelial ovarian cancer.

EXPERIMENTAL DESIGN

Expression of trypsinogen-1, trypsinogen-2, and TATI was determined by immunohistochemistry with monoclonal antibodies in tissue sections of tumors from 119 patients with untreated primary epithelial ovarian cancer. Preoperative serum concentrations of trypsinogen-2, trypsin-2-API and TATI were analyzed using specific immunoassays.

RESULTS

Fifty-four percent of the tumors expressed trypsinogen-1, 45% expressed trypsinogen-2, and 30% expressed TATI. In patients with stage III and IV disease, TATI tissue expression (P = 0.002) and elevated TATI concentration in serum (P = 0.048) were associated with adverse cancer-specific and progression-free survival in univariate analysis. In multivariate analysis, TATI tissue expression (P = 0.005), tumor grade (P = 0.0001), histological type (P = 0.02), and stage (P = 0.0005) were independent prognostic factors for adverse cancer-specific survival and TATI tissue expression (P = 0.006) and grade (P = 0.0003) for progression-free survival. In multivariate analysis of all patients and those with advanced disease, serum trypsin-2-API concentration was an adverse prognostic factor for cancer-specific and progression-free survival, and it was independent of stage and histological type of the tumor (P <or= 0.01).

CONCLUSIONS

Tissue expression of TATI and an elevated preoperative serum concentration of trypsin-2-API are strong independent prognostic factors in advanced epithelial ovarian cancer. These results suggest that trypsin expression plays a role in the progression of ovarian cancer. TATI and trypsin-2-API are of potential use as an aid for stratification of randomized studies and for selecting treatment strategies.

Authors+Show Affiliations

Department of Clinical Chemistry, Helsinki University Central Hospital, Helsinki, Finland. annukka.paju@hus.fiNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15269150

Citation

Paju, Annukka, et al. "Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-associated Trypsin Inhibitor in Ovarian Cancer: Prognostic Study On Tissue and Serum." Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, vol. 10, no. 14, 2004, pp. 4761-8.
Paju A, Vartiainen J, Haglund C, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004;10(14):4761-8.
Paju, A., Vartiainen, J., Haglund, C., Itkonen, O., von Boguslawski, K., Leminen, A., Wahlström, T., & Stenman, U. H. (2004). Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 10(14), 4761-8.
Paju A, et al. Expression of Trypsinogen-1, Trypsinogen-2, and Tumor-associated Trypsin Inhibitor in Ovarian Cancer: Prognostic Study On Tissue and Serum. Clin Cancer Res. 2004 Jul 15;10(14):4761-8. PubMed PMID: 15269150.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. AU - Paju,Annukka, AU - Vartiainen,Juhani, AU - Haglund,Caj, AU - Itkonen,Outi, AU - von Boguslawski,Kristina, AU - Leminen,Arto, AU - Wahlström,Torsten, AU - Stenman,Ulf-Håkan, PY - 2004/7/23/pubmed PY - 2005/1/20/medline PY - 2004/7/23/entrez SP - 4761 EP - 8 JF - Clinical cancer research : an official journal of the American Association for Cancer Research JO - Clin Cancer Res VL - 10 IS - 14 N2 - PURPOSE: The purpose is to study the prognostic significance of tissue expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor (TATI) and serum concentration of trypsinogen-2, trypsin-2-API (complex of trypsin-2 with alpha-1-proteinase inhibitor), and TATI in epithelial ovarian cancer. EXPERIMENTAL DESIGN: Expression of trypsinogen-1, trypsinogen-2, and TATI was determined by immunohistochemistry with monoclonal antibodies in tissue sections of tumors from 119 patients with untreated primary epithelial ovarian cancer. Preoperative serum concentrations of trypsinogen-2, trypsin-2-API and TATI were analyzed using specific immunoassays. RESULTS: Fifty-four percent of the tumors expressed trypsinogen-1, 45% expressed trypsinogen-2, and 30% expressed TATI. In patients with stage III and IV disease, TATI tissue expression (P = 0.002) and elevated TATI concentration in serum (P = 0.048) were associated with adverse cancer-specific and progression-free survival in univariate analysis. In multivariate analysis, TATI tissue expression (P = 0.005), tumor grade (P = 0.0001), histological type (P = 0.02), and stage (P = 0.0005) were independent prognostic factors for adverse cancer-specific survival and TATI tissue expression (P = 0.006) and grade (P = 0.0003) for progression-free survival. In multivariate analysis of all patients and those with advanced disease, serum trypsin-2-API concentration was an adverse prognostic factor for cancer-specific and progression-free survival, and it was independent of stage and histological type of the tumor (P <or= 0.01). CONCLUSIONS: Tissue expression of TATI and an elevated preoperative serum concentration of trypsin-2-API are strong independent prognostic factors in advanced epithelial ovarian cancer. These results suggest that trypsin expression plays a role in the progression of ovarian cancer. TATI and trypsin-2-API are of potential use as an aid for stratification of randomized studies and for selecting treatment strategies. SN - 1078-0432 UR - https://www.unboundmedicine.com/medline/citation/15269150/Expression_of_trypsinogen_1_trypsinogen_2_and_tumor_associated_trypsin_inhibitor_in_ovarian_cancer:_prognostic_study_on_tissue_and_serum_ L2 - http://clincancerres.aacrjournals.org/cgi/pmidlookup?view=long&amp;pmid=15269150 DB - PRIME DP - Unbound Medicine ER -